Hypercholesterolemia and hypertension in Mexico: urban conjunctive consolidation with obesity, diabetes and smoking

Agustín Lara; Martín Rosas; Gustavo Pastelín; Carlos Aguilar; Fause Attie; Óscar Velázquez Monroy

2004, Number 3

<< Back Next >>

Arch Cardiol Mex 2004; 74 (3)

Hypercholesterolemia and hypertension in Mexico: urban conjunctive consolidation with obesity, diabetes and smoking

Lara A, Rosas M, Pastelín G, Aguilar C, Attie F, Velázquez MO

Full text

How to cite this article

Language: Spanish
References: 26
Page: 231-245
PDF size: 220.88 Kb.

ABSTRACT

Aims: To know the prevalence and the interaction among the principal cardiovascular risk factors such as hypercholesterolemia (HCL), hypertension (HTA), overweight, carbohydrates metabolism disturbances, and smoking, an urban survey was performed in the six Mexican Republic states, where the national population is more concentrated. Methods: This survey was transversally designed using the WHO type-III model in 120,005 adults from 6 highly populated urban centers (Mexico City, Guadalajara, León, Puebla, Monterrey and Tijuana) were included. A blood sample from each person was obtained to quantify fasting glucose and cholesterol. Blood pressure, height and weight were measured using daily validated systems. Data were analyzed by a multicategorical conjunctive consolidation model and by multiple regression models. Results: HCL global prevalence showed to be 43.3% for a population with an average age of 44.1 years. Female gender showed a slightly but statistically significant greater prevalence of HCL than male gender (44% vs 42.2%). From whole women population 33.2% declared to be in menopause, and 59.7% of them had HCL. In addition, HCL was directly related to body mass index (BMI). Thus, in those subjects with BMI < 25 showed a HCL prevalence 34.1%; while those with BMI was between 25 and 29.9, the HCL prevalence was 45.9%, and in those subjects with BMI > 30 Kg/m2, ranked a HCL prevalence of 47.3%. The prevalence of hypertension was 30.2% and 52.5% of them had HCL prevalence. Type-2 diabetes mellitus prevalence (DM-2) was 10.7%, 55.2% of them had HCL. In the group aged between 20 to 34 years old, the obesity was the principal determinant for higher HCL prevalence. The HCL prevalence showed to be quite similar in population with and without smoking. In conclusion, HCL prevalence shows 4 progressively increasing gradients associated with age, HTA, DM-2 and BMI.

REFERENCES

Velazquez MO, Rosas PM, Lara EA, Pastelin HG, Grupo ENSA 2000, Attie F, Tapia CR: Hipertensión Arterial en México: Resultados de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2002; 72: 71-84.
Velazquez-Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelin Hernandez G, Sanchez-Castillo C, Attie F, Tapia Conyer R: Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Outcomes from the National Health Survey 2000. Arch Cardiol Mex 2003; 73(1): 62-77.
Collins R, MacMahon S: Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-98.
Zhang X, Patel A, Horibe H, et al for the Asia Pacific Cohort Studies Collaboration: Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003; 32: 563-72.
Grimm RH Jr, Margolis KL, Papademetriou VV, Cushman WC, Ford CE, Bettencourt J, et al: Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37: 19-27.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288(23): 2998-3007.
Skerrett PJ, Pasternak RC: ALLHAT-LLT: Questions, Questions, and More Questions (and Some Answers). Curr Atheroscler Rep 2004; 6: 375-80.
Barry RD, Furberg CD, Wright JT, Cutter JA, Whelton P. ALLHAT: Setting the record straight. Ann Intern Med 2004;141:39-46.
Brown WV, Mou8.8; .ssa M: Perspectives from :-the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial—Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm. Curr Opin Lipidol 2003; 14(6): 593-7.
Kastelein JJ: The future of lipid-lowering therapy: the big picture. Neth J Med 2003; 61(5 Suppl): 35-39.
Chapman N: New Evidence in hypertension and hyperlipidemia. Heart 2004; (90 Suppl IV): iv14-iv17.
Lawlor DA, Ebrahim S, May M, Davey SG: (Mis) use of factor analysis in the study of insulin resistance. Am J Epidemiol 2004; 159: 1013-1018.
Hanley AJ, Karter AJ, Festa A: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 2642-2647.
Arya R, Blangero J, Williams K: Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations chromosomes 6 and 7 in nondiabetic Mexican-Americans. Diabetes 2002; 51: 841-847.
Schemper M: Prevalence accuracy and explained variation. Stat Med 2003; 22: 2299-22308.
Feinstein AR: Multivariable Analysis: An introduction. New Haven Connecticut: Yale University Press, 1996: pp. 297-369.
Feinstein AR: Multivariable Analysis: An introduction. New Haven Connecticut: Yale University Press, 1996: pp. 111-119.
Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
User´s Guide: SPSS for windows. Advanced Statistics release 11.5 Chicago: SPSS; 2003: pp. 285-310.
Lteif A, Mather K: Insulin resistance, metabolic syndrome and vascular diseases: Update on mechanistic linkages. Can J Cardiol 2004; 20 Suppl B: 66B-76B.
Kim SH, Abbasi F, Reaven GM: Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 2004; 27(8): 1998-2002.
Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33(2): 283-303.
Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES: Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53(5): 1195-200.
Reaven GM: Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor’s clothes fit? Diabetes Care 2004; 27(4): 1011-2.
McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G: Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004; 53(4): 495-9.
Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, et al: High prevalence of metabolic syndrome in Mexico. Arch Med Res 2004; 35(1): 76-81.